HomeCompareRPHCF vs EQR

RPHCF vs EQR: Dividend Comparison 2026

RPHCF yields 1.82% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RPHCF wins by $43.18M in total portfolio value· pulled ahead in Year 3
10 years
RPHCF
RPHCF
● Live price
1.82%
Share price
$15.20
Annual div
$0.28
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.23M
Annual income
$39,107,153.37
Full RPHCF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — RPHCF vs EQR

📍 RPHCF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRPHCFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RPHCF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RPHCF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RPHCF
Annual income on $10K today (after 15% tax)
$154.90/yr
After 10yr DRIP, annual income (after tax)
$33,241,080.36/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, RPHCF beats the other by $33,236,426.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RPHCF + EQR for your $10,000?

RPHCF: 50%EQR: 50%
100% EQR50/50100% RPHCF
Portfolio after 10yr
$21.64M
Annual income
$19,556,314.49/yr
Blended yield
90.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

RPHCF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.2
Piotroski
5/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RPHCF buys
0
EQR buys
0
No recent congressional trades found for RPHCF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRPHCFEQR
Forward yield1.82%5.87%
Annual dividend / share$0.28$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%15.8%
Portfolio after 10y$43.23M$47.8K
Annual income after 10y$39,107,153.37$5,475.61
Total dividends collected$42.89M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: RPHCF vs EQR ($10,000, DRIP)

YearRPHCF PortfolioRPHCF Income/yrEQR PortfolioEQR Income/yrGap
1$11,064$364.47$11,380$679.82$316.00EQR
2$12,593$753.78$13,014$837.25$421.00EQR
3← crossover$15,078$1,603.54$14,961$1,036.20+$117.00RPHCF
4$19,722$3,588.75$17,297$1,289.22+$2.4KRPHCF
5$29,877$8,774.08$20,121$1,613.15+$9.8KRPHCF
6$56,812$24,844.41$23,561$2,030.84+$33.3KRPHCF
7$149,094$88,305.24$27,783$2,573.54+$121.3KRPHCF
8$592,694$433,162.94$33,013$3,284.39+$559.7KRPHCF
9$3,852,779$3,218,596.09$39,547$4,223.51+$3.81MRPHCF
10$43,229,627$39,107,153.37$47,791$5,475.61+$43.18MRPHCF

RPHCF vs EQR: Complete Analysis 2026

RPHCFStock

Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin; medicine for internal use, such as digestive and herbal medicines; oral medicines comprising gastrointestinal medicines, herbal medicines, and supplements; non-prescription medicines; and beauty counters that provide beauty and health services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. Rohto Pharmaceutical Co.,Ltd. was founded in 1899 and is headquartered in Osaka, Japan.

Full RPHCF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this RPHCF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RPHCF vs SCHDRPHCF vs JEPIRPHCF vs ORPHCF vs KORPHCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.